• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肺功能严重受损的囊性纤维化患者的死亡风险。

Risk of death in cystic fibrosis patients with severely compromised lung function.

作者信息

Milla C E, Warwick W J

机构信息

Cystic Fibrosis Center, University of Minnesota, Minneapolis, USA.

出版信息

Chest. 1998 May;113(5):1230-4. doi: 10.1378/chest.113.5.1230.

DOI:10.1378/chest.113.5.1230
PMID:9596299
Abstract

BACKGROUND

Lung disease accounts for most of the mortality in patients with cystic fibrosis (CF). Lung transplantation is an option for patients severely impaired, being recommended when life expectancy is estimated to be <2 years. Our objectives were to evaluate in our patient population the validity of currently accepted criteria for low life expectancy and to identify other potentially useful criteria.

METHODS

Data were retrieved from CF patients followed up at our center who reached and kept an FEV1 <30% predicted. A life table was created and stratified according to characteristics believed to be of importance. In addition, the rate of decline in percent predicted FEV1 was analyzed. These characteristics were evaluated as predictors of risk of death.

RESULTS

The median survival was 3.9 years (95% confidence interval, 2.88 to 4.12 years), with no significant differences according to gender, nutritional status, presence of diabetes, or decade in which the patient was cared for. Only by age was there a significant difference in the median survival (p<0.05). By proportional hazards regression, only the rate of decline in percent predicted FEV1 was a significant predictor of the risk of death, with a borderline effect from younger age (p=0.06).

CONCLUSION

In our patient population, a cutoff value of FEV1 of < 30% predicted is not a reliable predictor of high risk of death within 2 years. The yearly rate of decline of percent predicted FEV1 is a better parameter to identify those patients at high risk for death.

摘要

背景

肺部疾病是囊性纤维化(CF)患者死亡的主要原因。肺移植是重度受损患者的一种选择,当预期寿命估计小于2年时推荐进行。我们的目的是在我们的患者群体中评估目前公认的低预期寿命标准的有效性,并确定其他可能有用的标准。

方法

从我们中心随访的CF患者中检索数据,这些患者的第一秒用力呼气容积(FEV1)达到并维持在预测值的30%以下。创建生命表并根据被认为重要的特征进行分层。此外,分析预测FEV1百分比的下降率。这些特征被评估为死亡风险的预测因素。

结果

中位生存期为3.9年(95%置信区间,2.88至4.12年),根据性别、营养状况、是否存在糖尿病或患者接受治疗的年代,生存期无显著差异。仅年龄对中位生存期有显著差异(p<0.05)。通过比例风险回归分析,只有预测FEV1百分比的下降率是死亡风险的显著预测因素,年轻患者有临界效应(p=0.06)。

结论

在我们的患者群体中,FEV1预测值<30%不是2年内高死亡风险的可靠预测指标。预测FEV1百分比的年下降率是识别高死亡风险患者的更好参数。

相似文献

1
Risk of death in cystic fibrosis patients with severely compromised lung function.肺功能严重受损的囊性纤维化患者的死亡风险。
Chest. 1998 May;113(5):1230-4. doi: 10.1378/chest.113.5.1230.
2
Prediction of mortality in patients with cystic fibrosis.囊性纤维化患者死亡率的预测
N Engl J Med. 1992 Apr 30;326(18):1187-91. doi: 10.1056/NEJM199204303261804.
3
A model for predicting life expectancy of children with cystic fibrosis.
Eur Respir J. 2000 Dec;16(6):1056-60. doi: 10.1034/j.1399-3003.2000.16f06.x.
4
Heterogeneity in Survival in Adult Patients With Cystic Fibrosis With FEV < 30% of Predicted in the United States.美国预测FEV<30%的成年囊性纤维化患者生存的异质性
Chest. 2017 Jun;151(6):1320-1328. doi: 10.1016/j.chest.2017.01.019. Epub 2017 Jan 20.
5
Prognosis of patients with cystic fibrosis awaiting heart and lung transplantation.等待心肺移植的囊性纤维化患者的预后
J Heart Lung Transplant. 1993 Jul-Aug;12(4):669-74.
6
Clinical Outcomes and Prognostic Factors in a Cohort of Adults With Cystic Fibrosis: A 7-Year Follow-Up Study.成年囊性纤维化患者队列的临床结局及预后因素:一项7年随访研究
Respir Care. 2016 Feb;61(2):192-9. doi: 10.4187/respcare.04097. Epub 2015 Dec 29.
7
Reduced survival in adult cystic fibrosis despite attenuated lung function decline.尽管肺功能下降有所减缓,但成年囊性纤维化患者的生存率仍降低。
J Cyst Fibros. 2017 Jan;16(1):78-84. doi: 10.1016/j.jcf.2016.07.012. Epub 2016 Aug 10.
8
Prediction of mortality and timing of referral for lung transplantation in cystic fibrosis patients.囊性纤维化患者肺移植死亡率及转诊时机的预测
Pediatr Transplant. 2001 Oct;5(5):339-42. doi: 10.1034/j.1399-3046.2001.00019.x.
9
Risk factors for death of patients with cystic fibrosis awaiting lung transplantation.等待肺移植的囊性纤维化患者的死亡风险因素。
Am J Respir Crit Care Med. 2006 Mar 15;173(6):659-66. doi: 10.1164/rccm.200410-1369OC. Epub 2005 Dec 30.
10
Consequences of Expiratory Flow Limitation at Rest in Subjects with Cystic Fibrosis.囊性纤维化患者静息时呼气气流受限的后果
Ann Am Thorac Soc. 2016 Jun;13(6):825-32. doi: 10.1513/AnnalsATS.201508-485OC.

引用本文的文献

1
Development of a Miniaturized Mechanoacoustic Sensor for Continuous, Objective Cough Detection, Characterization and Physiologic Monitoring in Children With Cystic Fibrosis.用于囊性纤维化儿童连续、客观咳嗽检测、特征描述和生理监测的微型机械声传感器的研制。
IEEE J Biomed Health Inform. 2024 Oct;28(10):5941-5952. doi: 10.1109/JBHI.2024.3415479. Epub 2024 Oct 3.
2
Association of Oxygen Therapy with the Natural Disease Progression of Cystic Fibrosis: A Multi-State Model of the European Cystic Fibrosis Society Patient Registry.氧疗与囊性纤维化自然疾病进展的关联:欧洲囊性纤维化协会患者登记处的多状态模型
Ther Clin Risk Manag. 2023 Mar 13;19:255-267. doi: 10.2147/TCRM.S391476. eCollection 2023.
3
Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation.
肺移植候选人选择的共识文件:国际心肺移植学会的更新。
J Heart Lung Transplant. 2021 Nov;40(11):1349-1379. doi: 10.1016/j.healun.2021.07.005. Epub 2021 Jul 24.
4
The Treatment of Disability under Crisis Standards of Care: An Empirical and Normative Analysis of Change over Time during COVID-19.危机标准下的残疾治疗:COVID-19 期间随时间变化的实证与规范分析。
J Health Polit Policy Law. 2021 Oct 1;46(5):831-860. doi: 10.1215/03616878-9156005.
5
Cardiorespiratory fitness on a treadmill in an adult cystic fibrosis population.成年囊性纤维化患者群体在跑步机上的心肺适能
BMJ Open Sport Exerc Med. 2020 Aug 17;6(1):e000765. doi: 10.1136/bmjsem-2020-000765. eCollection 2020.
6
Clinical characteristics and outcomes in adult cystic fibrosis patients with severe lung disease in Porto Alegre, southern Brazil.巴西南部阿雷格里港成人囊性纤维化伴严重肺部疾病患者的临床特征和结局。
BMC Pulm Med. 2020 Jul 16;20(1):194. doi: 10.1186/s12890-020-01223-6.
7
Timing it right: the challenge of recipient selection for lung transplantation.把握时机:肺移植受者选择的挑战
Ann Transl Med. 2020 Mar;8(6):408. doi: 10.21037/atm.2019.11.61.
8
Indications for lung transplant referral and listing.肺移植转诊及列入名单的指征。
J Thorac Dis. 2019 Sep;11(Suppl 14):S1708-S1720. doi: 10.21037/jtd.2019.05.09.
9
A Novel Tool to Evaluate the Accuracy of Predicting Survival and Guiding Lung Transplantation in Cystic Fibrosis.一种评估囊性纤维化患者生存预测准确性及指导肺移植的新型工具。
Epidemiology (Sunnyvale). 2019;9(2). doi: 10.4172/2161-1165.1000375. Epub 2019 Jun 17.
10
Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelines.肺移植转诊推荐:囊性纤维化基金会共识指南。
J Cyst Fibros. 2019 May;18(3):321-333. doi: 10.1016/j.jcf.2019.03.002. Epub 2019 Mar 27.